A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B

Summary

This three-part, Phase 1 protocol will be the first clinical study of ABI-H2158. Parts 1 and 2 will be a Phase 1a, dose-ranging assessment of ABI-H2158 in healthy adult volunteers. If the dose-related safety, tolerability, and pharmacokinetics (PK) of ABI-H2158 in healthy volunteers are deemed satisfactory, then the study will advance to Part 3, a Phase 1b, dose-ranging assessment of ABI-H2158 in non-cirrhotic, CHB patients.

Timeline

Start

2018-11-13

Primary completion

2020-11-23

Completion

2021-01-07

Drugs

Indications